Credit: National Cancer Institute In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression ...
Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...
Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase that regulates signaling pathways controlling cell survival and proliferation. Dysregulation of FGFR2, through ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...
Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...
Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...
CHICAGO, June 2, 2026 /PRNewswire/ — At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827.
Bottom Line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results